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Abstract
Background: The feasibility of drug monitoring of serum concentrations of morphine, morphine-
6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not
established. One important factor relevant to drug monitoring is to what extent morphine, M6G
and M3G serum concentrations fluctuate during stable morphine treatment.
Methods: We included twenty-nine patients admitted to a palliative care unit receiving oral
morphine (n = 19) or continuous subcutaneous (sc) morphine infusions (n = 10). Serum
concentrations of morphine, M6G and M3G were obtained at the same time on four consecutive
days. If readmitted, the patients were followed for another trial period. Day-to-day variations in
serum concentrations and ratios were determined by estimating the percent coefficient of variation
(CV = (mean/SD) ×100).
Results: The patients' median morphine doses were 90 (range; 20–1460) mg/24 h and 135 (range;
30–440) mg/24 h during oral and sc administration, respectively. Intraindividual fluctuations of
serum concentrations estimated by median coefficients of day-to-day variation were in the oral
group for morphine 46%, for M6G 25% and for M3G 18%. The median coefficients of variation were
lower in patients receiving continuous sc morphine infusions (morphine 10%, M6G 13%, M3G 9%).
Conclusion: These findings indicate that serum concentrations of morphine and morphine
metabolites fluctuate. The fluctuations found in our study are not explained by changes in morphine
doses, administration of other drugs or by time for collection of blood samples. As expected the
day-to-day variation was lower in patients receiving continuous sc morphine infusions compared
with patients receiving oral morphine.
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Morphine is degraded in the liver to several metabolites of
which morphine-6-glucuronide (M6G) and morphine-3-
glucuronide (M3G) are biological active [1]. M6G is
shown to contribute to the analgesia produced by mor-
phine and may cause opioid related adverse effects such as
sedation or nausea [2-5]. Due to first pass metabolism and
slow accumulation of M6G in the brain the analgesic
activity of M6G is most prominent during oral long-term
treatment with morphine while single dose studies show
less contribution from M6G to the analgesic effects from
morphine [2,3,6]. M3G may in exceptional cases cause
excitatory adverse effects such as delirium, myoclonus or
allodynia [7]. Animal studies observed that M3G have an
anti-nociceptive effect [8,9], but this effect was not repro-
duced in a study administering M3G to volunteers
exposed for human experimental pain [10].
The most obvious determinants for serum concentrations
of morphine, M6G and M3G are morphine doses, route of
administration and renal function. However, a considera-
ble variation of serum concentrations between patients
remains after correcting for dose and route of administra-
tion [3,11-13].
Measurements of morphine, M3G and M6G serum con-
centrations can explain individual responses in patients
where morphine treatment turns out to have unexpected
effects and help physicians to determine changes in pain
treatment. Physicians tend to believe that samples
obtained for therapeutic drug monitoring during steady
state conditions will be representative irrespective of
which day the sample is collected. However, morphine,
M6G and M3G serum concentrations may also have fluc-
tuations not caused by changes in morphine doses,
administration of other drugs or by time for collection of
blood samples. This variation represents the day-to-day
variability. In order to evaluate the clinical implications
from morphine and metabolites serum concentrations
measurements it is necessary to know if these serum con-
centrations have fluctuations not related to changes in
drug administrations.
The day-to-day variability in serum concentrations of
morphine, M6G and M3G are previously reported in a
study of 8 cancer patients treated with subcutaneous (sc)
morphine infusions. This study observed coefficients of
variation (CV) ranging from 26%–56% for morphine,
20% to 51% for M6G and 20%–49% for M3G [12]. To
our knowledge, the day-to-day variations of morphine,
M6G and M3G serum concentrations obtained from con-
secutive days or during chronic oral administration of
morphine are not previously reported.
Thus, the aim of this study is to investigate the day-to-day
variations of morphine, M6G and M3G serum concentra-
tions during stable chronic oral and sc morphine admin-
istration to cancer patients.
Methods
Patients
We included twenty-nine patients admitted during a nine-
month period to the Palliative Care Unit at the University
Hospital in Trondheim. The inclusion criteria were; veri-
fied malignant disease, expected survival time less than 6
months, scheduled morphine treatment started at least
three days prior to inclusion, stable scheduled doses of
morphine for a minimum of three days and age more
than eighteen years. The exclusion criteria were; planned
hospitalisation less than three days and lack of ability to
communicate (e.g. dementia, deafness).
All patients gave their written informed consent before
inclusion. The study was conducted according to the
guidelines of the Helsinki declaration. The Regional Com-
mittee for Medical Research Ethics, Health Region IV,
Norway, approved the study.
Study design
Inclusion
The patients were included in the study within three days
after admission to the Palliative Care Unit. Each patient
was followed for four days. Patients readmitted to the Pal-
liative Care Unit were allowed to a new trial period iden-
tical to the first trial period. No patients were included in
more than three trial periods.
The patients' age, gender, primary malignant diagnosis,
presence of metastasis, and other medications were regis-
tered. Morphine treatment during the last 24 hours was
registered with respect to route of administration, mor-
phine formulation, scheduled dose and consumption of
rescue morphine for breakthrough pain. The patients'
functional status was assessed using the Karnofsky per-
formance status score [15].
Blood samples
Blood samples were obtained each day during the trial
period. The samples were obtained at the same time each
day during the routine morning round for collecting
blood samples.
Observations
In order to observe if the patients were studied during sta-
ble treatment conditions the scheduled morphine dose,
rescue morphine consumption and route of administra-
tion were registered each study day. The use of other med-
ications was also registered daily. Pain, nausea and
sedation were assessed at day study two, three and fourPage 2 of 7
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scale (VRS) score ranging from no to very severe. All symp-
toms were assessed for the last 24 h.
Analyses
The blood samples were placed in EDTA tubes until sepa-
rated by centrifugation (3000 rpm, ten minutes) and
stored at -85°C until analysed. All samples were analysed
for serum concentrations of morphine, M6G and M3G
applying liquid chromatography mass spectrometry [16].
The limits of detection were for morphine 0,35 nmol/l
and for M6G and M3G 2,2 nmol/l. The analytical coeffi-
cients of variation obtained in quality control samples
(CVAnalytical) were for morphine 3,0%, for M6G 5,5% and
for M3G 7,0%. The analytical coefficients of variation
were determined at 100 nmol/l for morphine and 1000
nmol/l for M6G and M3G. Serum values of creatinine
concentrations, alanin aminotransferase activities (ALAT),
aspartat aminotransferase activities (ASAT) and albumin
concentrations were determined using standard analytical
methods.
Statistical evaluation
Total use of morphine for each trial day was calculated by
adding scheduled morphine doses and rescue morphine
consumption. Samples obtained less than two hour after
the administration of a morphine rescue dose were
excluded from the analyses.
Day-to-day variations of morphine and its metabolites are
presented as biological coeffecients of variation. This bio-
logical variation (CVBiological), expressed in terms of per-
cent coefficient of variation, was calculated for each
patient in each trial period using the equation [15,16]:
CVBiological = CVObserved - CVAnalytical
The observed coefficients of variation (CVObserved) for
morphine, M6G and M3G, which represent the variation
in serum concentrations for each patient during each trial
period, were calculated using the equation [17,18]:
At least three observations were needed in order to calcu-
late an observed coefficient of variation.
Statistical comparisons between the trial days and trial
periods were performed using one-way analysis of vari-
ance tests. Due to multiple comparisons statistical signifi-
cance was defined as p < 0,01.
The statistical software SPSS version 9.0 for Windows was
used throughout the analyses.
Results
Patient characteristics
The patients (16 males and 13 women) median age at
inclusion was 68 years (range; 39–89). The patients'
Karnofsky performance status, primary tumor diagnoses
and presence of metastases are shown in Table 1. The
median serum creatinine concentrations at inclusion were
Table 1: Patient characteristics
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sion of ASAT and ALAT were 31 IU/l (range; 7–154) and
17 IU/l (range; 5–65), respectively. No patient had clini-
cal significant liver failure. The median serum albumin
concentrations at inclusion were 32 g/l (range; 23–42).
Ten patients used non-opioid analgesics (nine paraceta-
mol, one acetylsalicylic acid). The patients used a median
number of 5 (range; 1–10) non-pain medications. The
numbers of patients using psychotropic drugs, antiemet-
ics or corticosteroids are given in Table 1. All except one
patients received laxatives, lactulose and bisacodyl, during
the study period. All medications were stable during the
study period. Similar pain, nausea and sedation scores
were observed throughout the trial periods (Table 2).
Twenty-seven patients had died at the time of manuscript
preparation. The median survival time from inclusion was
three months.
Of the nineteen patients receiving oral morphine sixteen
patients completed one trial period, two patients com-
pleted two trial periods and one patient completed three
trial periods. The corresponding numbers for the ten
patients receiving sc morphine were four, five and one,
respectively. Six patients were excluded during a study
period. The reasons were; discharge from hospital (n = 2),
opioid treatment changed to fentanyl patch (n = 1) and
fatigue (n = 3). Opioid induced adverse effects caused no
exclusions. Sixteen blood samples were not obtained due
to circumstances related to the patients' or relatives' needs
(e.g. visits from relatives at the time of a planned blood
sample).
Morphine treatment
The median duration of morphine treatment before enter-
ing the study was 7 months (range; 0–29). The median
morphine dose at inclusion for the patients receiving oral
treatment (controlled-release morphine) was 90 mg/24 h
(range; 20–1460). The median morphine dose for the
patients receiving sc morphine infusions was 135 mg/24
h (range; 30–340). The morphine doses varied between
the study days because the patients were allowed to use
rescue morphine. This variation, however, was minor
(Table 3 and 4).
The diurnal distributions of rescue morphine administra-
tions were recorded in order to assess the possible influ-
ence from rescue morphine on the serum concentration
observations. Three blood samples were obtained during
the two-hour interval following an administration of res-
cue morphine. The results from these samples were
excluded from the analyses.
Morphine, M6G and M3G serum concentrations
The median serum concentrations of morphine during
oral morphine treatment ranged from 59 to 255 nmol/l
during the four study days. The median serum concentra-
tions for M6G and M3G on each study day for patients
receiving oral morphine are given in Table 3.
The median serum concentrations were more stable dur-
ing sc morphine treatment compared with oral treatment.
The median serum concentrations of morphine during sc
morphine treatment ranged from 240 to 373 nmol/l dur-
ing the study days. The median serum concentrations for
Table 2: Symptom scores All scores were obtained using a 5 category verbal rating scale score (scores; 1–5). All results are given as 
mean (SD). No significant differences in scores were observed between trial days.
Trial day 2 Trial day 3 Trial day 4
Pain 2.8 (0.7) 2.2 (1.1) 2.2 (1,1)
Nausea 1.7 (1.0) 1.7 (1.1) 1.8 (0.9)
Sedation 3.4 (1.2) 3.4 (1.0) 3.2 (1.1)
Table 3: Serum concentrations for morphine and metabolites for the oral route The morphine doses (mg/24 h) vary because of variable 
doses of rescue morphine. A total of 23 trial periods in 19 patients were studied. All data are given as median and range.
Day 1 Day 2 Day 3 Day 4
Morphine dose (mg/24 h) 90 (20–1460) 80 (20 – 1700) 95 (30 – 1520) 90 (20 – 1580)
Serum morphine (nmol/l) 255 (46–2520) 59 (17–1437) 94 (12–1429) 77 (9–2296)
Serum M6G (nmol/l) 1156 (149–7874) 568 (66–7874) 516 (66–9678) 620 (80–8026)
Serum M3G (nmol/l) 6341 (1734–31997) 3696 (404–36887) 3226 (595–41452) 3778 (526–43043)Page 4 of 7
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morphine are given in Table 4.
Day-to-day variation
The median biological coefficient of variation (CV) for
morphine serum concentrations was 46% (range; 13–
103) during oral morphine therapy and 10% (range; 0–
36) during sc morphine infusions (Table 5). The median
biological CV values for M6G were 25% (range; 1–72)
during oral therapy and 13% (range; 2–40) during s.c.
therapy. The corresponding results for M3G serum con-
centrations were 18% (range; 0–57) and 9% (range; 0–
34), respectively (Table 5).
Discussion
Intraindividual fluctuation of drug serum concentrations
not explained by changes in doses, administration of
other drugs or by time for collection of blood samples, is
the day-to-day variation. Routine measurements of serum
concentrations of morphine and metabolites are of ques-
tionable value because of the large variability of mini-
mum effective serum concentration and the lack of a
direct relationship between serum concentrations and
adverse effects [19]. However, measurements of serum
concentrations of morphine and metabolites are of
importance in patients displaying unexpected opioid tox-
ity [4,7] Physicians assessing results from serum drug con-
centrations determinations should be aware to what
extent serum concentrations of drugs fluctuate during sta-
ble treatment conditions. Without this knowledge differ-
ences and changes in serum concentrations observations
may be unduly interpreted.
The available data on day-to-day variability during
chronic morphine treatment is sparse. Vermeire et al.
reported day-to-day variations during morphine treat-
ment in eight cancer patients receiving continuous sc mor-
phine infusion for 1 to 23 weeks. The individual CV
values observed in their study varied between 26% to 56%
for morphine, 20% to 51% for M6G and 20% to 49% for
M3G [14].
We observed less day-to-day variations of morphine and
metabolites concentrations during sc morphine treatment
(morphine 10%, M6G 13%, M3G 9%) compared to the
fluctuations reported by Vermeire et al.. One explanation
for this discrepancy is that Vermeire et al. obtained blood
samples during treatment periods up to 23 weeks. This
study design may overestimate day-to-day variability since
patient related factors will vary more during long time
intervals than between consecutive days.
To our knowledge this is the first study to assess the day-
to-day variation of morphine and morphine metabolites
serum concentrations during oral morphine therapy. The
median observed CV values for serum concentrations of
morphine, M6G and M3G during oral morphine therapy
(morphine 46%, M6G 25%, M3G 18%) were higher than
the CV values observed in patients receiving sc morphine
treatment (morphine 10%, M6G 13%, M3G 9%). This
Table 4: Serum concentrations for morphine and metabolites for the subcutaneous route The morphine doses (mg/24 h) vary because 
of variable doses of rescue morphine. A total of 17 trial periods in 10 patients were studied. All data are given as median and range.
Day 1 Day 2 Day 3 Day 4
Morphine dose (mg/24 h) 135 (30–340) 163 (30 – 335) 164 (50 – 440) 150 (84 – 440)
Serum morphine (nmol/l) 240 (42–741) 254 (62–1297) 305 (106–1045) 373 (103–1222)
Serum M6G (nmol/l) 723 (78–1811) 674 (88–2867) 1009 (374–2023) 1225 (400–2339)
Serum M3G (nmol/l) 5350 (578–11784) 4490 (779–16312) 5631 (3028–8342) 6119 (2777–13715)
Table 5: Biological coefficients of variation (CV) of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) 
serum concentrations during four consecutive days of oral or subcutaneous morphine treatment. All values are given as median and 
range.
Biological coefficient of variation %
Oral morphine Subcutaneous morphine
Morphine 46 (13–103) 10 (0–36)
M6G 25 (1–72) 13 (2–40)
M3G 18 (0–57) 9 (0–34)Page 5 of 7
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rate and since absorption during sc administration is not
influenced by food intake, gastric retention, malabsorp-
tion, vomiting or variable first-pass metabolism.
The results in our study, as in the study by Vermeire et al.,
represent day-to-day variability in cancer patients admit-
ted to a palliative care unit. In this patient population
pharmacological observations will be influenced by varia-
tions in food intake, gastric retention, malabsorption,
effects from other drugs on gastric emptying, vomiting
and drug interactions. In order to perform a study on day-
to-day variation not suspect to these confounding factors
patients or volunteers must be recruited into a controlled
experimental environment. We believe that studies in
controlled experimental environments and studies in
patients with advanced cancer disease are complementary
to each other. The first targets the pharmacokinetic phe-
nomenon of day-to-day fluctuations, the second targets
the fluctuations met during clinical real-life conditions.
We recognise some limitations in our study. First, blood
samples were collected during four trial days. An extended
trial period in order to obtain a larger number of samples
from each patient gives a more precise estimate of day-to-
day variation. However, due to ethical considerations, tak-
ing into account the strain on each patient from serial
blood sampling, we chose to not extend the trial periods
beyond four days. A second potential confounding factor
is absorption peaks in serum concentrations caused by
rescue doses of morphine. We chose to allow for rescue
morphine because we wanted to observe the variability of
serum concentrations as observed in a normal clinical set-
ting in patients considered to be clinical stable in respect
to pain treatment. We belive that the variability caused by
serum concentration peaks is limited since samples
obtained within a time interval of two hours after admin-
istration of a morphine rescue dose were excluded. How-
ever, it is important to recognize that in order to observe
the exact pharmacological day-to-day variability of serum
concentrations of morphine and morphine metabolites a
design with a stable baseline morphine dose and a non-
morphine alternative for breakthrough pain should be
applied. Third, the use of rescue morphine implies that
the daily morphine doses were not constant. However, the
small changes in daily morphine doses can not explain
the observed day-to-day variability.
In this study we assessed clinical symptoms related to opi-
oid treatment in order to verify the stable intensities of
symptoms during the study period. We did not attempt to
explore the relationships between serum concentrations
and clinical outcome measures. As a rule of thumb 25
patients are required per independent variable in order to
give valid results in studies exploring the effects from fac-
tors predicting clinical observations [20]. Consequently,
the size of this study was not sufficient to investigate the
relationships between opioid serum concentrations and
clinical symptoms.
Conclusions
Morphine, M6G and M3G serum concentrations vary con-
siderably in samples obtained on consecutive days. Such
variability is present during stable morphine doses and
stable clinical symptoms. The day-to-day variability was
lower in patients receiving continuous sc morphine infu-
sions compared with patients receiving oral morphine.
These findings indicate that results from blood samples
taken in order to assess a patient's pharmacological mor-
phine status should be interpreted with the understanding
of that variability is partly caused by day-to-day variation.
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